Decision Tool Reduces Antidepressant Discontinuation in Depression
A web-based system personalizing antidepressant selection kept more patients on therapy at 8 weeks and improved symptoms at 24 weeks.
Obinutuzumab Shows High Efficacy in Active Systemic Lupus Erythematosus
A phase 3 trial shows the anti-CD20 antibody obinutuzumab significantly improves clinical responses and reduces flares in active lupus.
Pimicotinib Yields 54% Response in Tenosynovial Giant Cell Tumors
The selective inhibitor pimicotinib demonstrates high efficacy for unresectable joint tumors while avoiding severe hepatotoxicity.
Zorevunersen Cuts Convulsive Seizures in Children With Dravet Syndrome
The investigational antisense therapy reduced convulsive-seizure frequency by up to 90.91% and improved adaptive behavior over 36 months.
Finerenone Reduces Albuminuria in Type 1 Diabetes and CKD
A phase 3 trial shows the mineralocorticoid receptor antagonist finerenone safely lowers albuminuria in adults with type 1 diabetes.
Baxdrostat Reduces 24-Hour Blood Pressure in Resistant Hypertension
A phase 3 trial shows the selective aldosterone synthase inhibitor baxdrostat reduces systolic blood pressure by 14 mm Hg versus placebo.
Neoadjuvant GOLP Doubles Event-Free Survival in Cholangiocarcinoma
Administering the GOLP regimen before surgery extends median event-free survival to 18 months in high-risk intrahepatic cholangiocarcinoma.
Hybrid Dialectical Behavior Therapy Reduces Suicidal Ideation in Adolescents
A year-long trial shows combining online and offline DBT improves emotional regulation and depressive symptoms in self-injuring youth.
Apixaban Reduces Bleeding Risk Versus Rivaroxaban in Venous Thromboembolism
In a randomized trial of 2,760 patients, apixaban resulted in a 3.3% bleeding rate compared to 7.1% for rivaroxaban over three months.
Romiplostim Prevents Chemotherapy Dose Reductions in Gastrointestinal Cancers
A phase 3 trial shows romiplostim maintains platelet counts, allowing patients to receive full oxaliplatin-based chemotherapy doses.
Inhaled Treprostinil Slows FVC Decline in Idiopathic Pulmonary Fibrosis
A phase 3 trial shows inhaled treprostinil preserves forced vital capacity and reduces clinical worsening over 52 weeks versus placebo.
Clozapine Increases Response After One Failed Antipsychotic in Early Psychosis
A sequential trial reveals that switching to clozapine after a single failed antipsychotic yields a 62.5% response rate in early psychosis.